Journal
BIOMATERIALS
Volume 34, Issue 10, Pages 2524-2529Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2012.12.030
Keywords
Poly alpha-hydroxy acids; Microparticles; Vaccine; Cancer; Antigen; Adenovirus
Funding
- American Cancer Society [RSG-09-015-01-CDD]
- National Cancer Institute at the National Institutes of Health [1R21CA13345-01/UI Mayo Clinic Lymphoma SPORE/P50CA09727411]
Ask authors/readers for more resources
Adenoviruses show promising potential as vectors for cancer vaccines, however, their high immunogenicity can be problematic when it comes to homologous prime-boost strategies. In the studies presented here we show that heterologous prime-boost vaccinations involving ovalbumin (OVA)-antigen-coated microparticles as a prime, and adenovirus encoding OVA (AdOVA) as a boost, were equally as effective as homologous AdOVA prime-boosts at generating OVA-specific CD8(+) T-cell responses, which translated into effective tumor protection. OVA-coated biodegradable poly alpha-hydroxy acid-based microparticles of varying chemistries, when used as primes in heterologous prime-boost vaccinations, were comparable in terms of promoting OVA-specific CD8(+) T cells as well as providing protection against subsequent tumor challenge. These findings auger well for using poly alpha-hydroxy acid-based microparticles in prime-boost viral vaccination strategies geared toward the safer, and potentially more efficient, generation of anti-tumor immunity. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available